CALZETTA, LUIGINO
 Distribuzione geografica
Continente #
NA - Nord America 24.032
AS - Asia 1.567
EU - Europa 1.478
SA - Sud America 34
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
AF - Africa 6
Totale 27.136
Nazione #
US - Stati Uniti d'America 24.016
SG - Singapore 624
KR - Corea 470
CN - Cina 393
IE - Irlanda 331
IT - Italia 238
UA - Ucraina 206
RU - Federazione Russa 170
DE - Germania 166
FR - Francia 90
GB - Regno Unito 87
SE - Svezia 62
FI - Finlandia 49
ID - Indonesia 25
BR - Brasile 22
PL - Polonia 22
NL - Olanda 16
BE - Belgio 15
CA - Canada 14
IN - India 9
A2 - ???statistics.table.value.countryCode.A2??? 8
AU - Australia 8
CL - Cile 7
ES - Italia 7
GR - Grecia 5
HK - Hong Kong 5
JP - Giappone 5
MY - Malesia 5
PH - Filippine 5
RO - Romania 5
EC - Ecuador 4
EG - Egitto 4
JO - Giordania 3
KH - Cambogia 3
UZ - Uzbekistan 3
AT - Austria 2
EU - Europa 2
IR - Iran 2
MK - Macedonia 2
NP - Nepal 2
SA - Arabia Saudita 2
TR - Turchia 2
VN - Vietnam 2
BD - Bangladesh 1
BG - Bulgaria 1
CO - Colombia 1
CR - Costa Rica 1
GT - Guatemala 1
HU - Ungheria 1
IQ - Iraq 1
KE - Kenya 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TW - Taiwan 1
Totale 27.136
Città #
Wilmington 7.199
Houston 7.101
Woodbridge 4.586
Fairfield 1.056
Singapore 528
Ann Arbor 478
Chandler 478
Ashburn 455
Seattle 436
Cambridge 368
Dublin 253
Dearborn 214
Medford 187
Beijing 121
Santa Clara 115
Jacksonville 92
Lawrence 92
New York 86
Rome 83
Zhengzhou 69
San Diego 57
Menlo Park 41
Redwood City 30
Jakarta 23
London 23
Moscow 23
Kraków 20
Milan 20
Norwalk 20
Shanghai 20
Nanjing 18
Guangzhou 17
Hefei 16
Brussels 15
Helsinki 15
Hangzhou 14
Palo Alto 13
Seoul 13
Jinan 12
La Veta 11
Saint Petersburg 11
Mountain View 10
Verona 10
Wuhan 10
Boardman 9
Kunming 9
Nanchang 9
San Jose 9
Los Angeles 8
Naples 8
Chengdu 7
Phoenix 7
São Paulo 7
Council Bluffs 6
Kilburn 6
Toronto 6
Athens 5
Hamilton 5
Jiaxing 5
Nuremberg 5
Hong Kong 4
Lappeenranta 4
New Bedfont 4
Osaka 4
Prescot 4
Redmond 4
San Francisco 4
Amsterdam 3
Bari 3
Bologna 3
Cagliari 3
Chaah 3
Cuenca 3
Detroit 3
Frankfurt am Main 3
Frosinone 3
Fuzhou 3
Manila 3
Nizhniy Novgorod 3
Phnom Penh 3
Raleigh 3
San Mateo 3
Washington 3
Wenzhou 3
Xi'an 3
Acerra 2
Agropoli 2
Barga 2
Baulkham Hills 2
Belo Horizonte 2
Birmingham 2
Coalville 2
Colorado Springs 2
Costa Mesa 2
Engelhard 2
Guiyang 2
Gunzenhausen 2
Hanoi 2
Hanover 2
Harbin 2
Totale 24.682
Nome #
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation 441
Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness 435
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases 426
A Novel and Effective Balanced Intravenous-Inhalant Anaesthetic Protocol in Swine by Using Unrestricted Drugs 423
Withdrawal of inhaled corticosteroids in COPD: A meta-analysis 423
Optimizing drug delivery in COPD: The role of inhaler devices 423
Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease 419
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 418
Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis 418
Tiotropium formulations and safety: a network meta-analysis 417
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis 416
Can a better patients' phenotyping predict the efficacy of tiotropium in symptomatic asthma? 414
Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents? 412
Is allergic sensitization to siberian hamster preventable in high-risk individuals who are already sensitized or exposed to furry animals? 407
Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in “real life”? 407
Occupational allergy to horse allergens: More than exposure to horses! 402
Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD 401
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi 393
The Challenges of Precision Medicine in COPD 392
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 390
Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies 388
Clinical effect of corticosteroids in asthma-affected horses: A quantitative synthesis 386
Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience 382
Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical practice!): Why the questions should be simplified? 378
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi 376
Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals? 371
Critical aspects in dog allergen immunotherapy (DAI). May Component Resolved Diagnosis (CRD) play a role in predicting the efficacy? 367
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study 366
Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways 363
Gastroesophageal reflux and COPD exacerbations: Is cholinergic-mediated oesophago-bronchial reflex a possible link? 361
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis 361
Dysfunction of small airways and prevalence, airway responsiveness and inflammation in asthma: much more than small particle size of pet animal allergens 360
What could the role of can f 5 allergen be in dog-sensitized patients in “real life”? 360
null 359
Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics 349
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis 348
Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine 344
Partial renal resection by LaparoNewPro: in vivo open and laparoscopic study in an animal model 343
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: An Italian Multicenter Study 336
Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways 336
Relationship between oxytocin/vasopressin and latex in obstetric surgery: How to recognize (and prevent) allergic reactions and differentiate them from side effects? 336
Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus 328
Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma 327
Anaphylaxis and intimate behaviour 327
Anxiety and asthma in youth. Is a stress-induced increased cholinergic tone the possible link? 327
Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis 326
Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue 325
Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how 315
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis 301
Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi 284
Is ICS–LAMA an alternative option to treat patients with COPD? 270
Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells 269
Indoor environmental interventions for furry pet allergens: How to decrease the degree of passive transport 263
Psychological Stress, Lung Function and Exacerbation Risk in COPD: Is an Increase of Cholinergic Tone a Possible Link? 252
The safety of dual bronchodilation on cardiovascular serious adverse events in COPD 250
Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease 249
Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine 248
Geographical characteristics influencing the risk of poisoning in pet dogs: Results of a large population-based epidemiological study in Italy 247
How does race/ethnicity influence pharmacological response to asthma therapies? 247
Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients 245
The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: A quantitative synthesis 240
Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach? 240
Cardiovascular Disease in Chronic Respiratory Disorders and Beyond 219
Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment 217
Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection? 216
Allergy in adolescent population (14-18 years) living in Campania region (southern Italy): a multicenter study 213
Impact of doxofylline in COPD: A pairwise meta-analysis 213
Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple combination therapy in COPD 211
N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation 209
Olodaterol + tiotropium bromide for the treatment of COPD 208
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine 199
LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review 198
Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease 193
Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics 193
Anthelminthic medicinal plants in veterinary ethnopharmacology: A network meta-analysis following the PRISMA-P and PROSPERO recommendations 191
Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it 190
Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis 184
Bronchodilators in subjects with asthma-related comorbidities 182
Dog allergy: Can a prevalent or exclusive sensitization to can f 5 be considered a lucky or negative event in “real life”? 181
Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice? 177
Efficacy and safety profile of doxofylline compared to theophylline in asthma: A meta-analysis 174
Monoclonal antibodies in severe asthma: is it worth it? 173
Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis 163
Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics 156
Monoclonal antibodies for severe asthma: Pharmacokinetic profiles 155
Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations 153
Occupational exposure to furry animals and asthma: The complex interconnection between work and everyday life 144
Clinical efficacy of bronchodilators in equine asthma: Looking for minimal important difference 140
Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways 127
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD 123
Response 122
Sex differences in adult asthma and COPD therapy: a systematic review 51
Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score 39
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD 39
Are there pulmonary sequelae in patients recovering from COVID-19? 32
Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium/vilanterol fixed-dose combination in chronic obstructive pulmonary disease 31
Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab" 30
Immunoprophylaxis pharmacotherapy against canine leishmaniosis: A systematic review and meta-analysis on the efficacy of vaccines approved in European Union 30
Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD) 27
The Impact of Corticosteroids on Human Airway Smooth Muscle Contractility and Airway Hyperresponsiveness: A Systematic Review 26
Totale 27.256
Categoria #
all - tutte 61.720
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.720


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.385 0 0 0 0 0 989 855 823 848 701 598 571
2020/20215.104 559 604 602 603 574 611 616 500 94 154 124 63
2021/2022951 78 83 19 21 26 114 64 42 52 131 111 210
2022/20231.160 121 95 40 156 106 275 99 62 121 5 45 35
2023/2024482 151 13 36 10 33 94 39 12 13 25 7 49
2024/20251.333 96 601 309 140 118 69 0 0 0 0 0 0
Totale 27.610